Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YL 202

Next Previous
Drug Profile

YL 202

Alternative Names: BNT-326; YL-202

Latest Information Update: 16 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediLink Therapeutics
  • Developer BioNTech; MediLink Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • Phase I HER2 negative breast cancer

Most Recent Events

  • 10 Mar 2026 MediLink Therapeutics plans a phase III trial for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Recurrent) in China (IV, Infusion), in March 2026 (NCT07461454)
  • 18 Feb 2026 MediLink Therapeutics plans phase III in Non small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy and greater, Combination therapy and Monotherapy) in China in March 2026 (IV) (NCT07416994)
  • 01 Oct 2025 MediLink Therapeutics plans a phase II trial in Solid tumours (Late-stage disease, Metastatic disease, Second line therapy or greater) in China in October 2025 (IV, Infusion) (NCT07202364)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top